These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Streptococcus pneumoniae fructose-1,6-bisphosphate aldolase, a protein vaccine candidate, elicits Th1/Th2/Th17-type cytokine responses in mice. Elhaik Goldman S; Dotan S; Talias A; Lilo A; Azriel S; Malka I; Portnoi M; Ohayon A; Kafka D; Ellis R; Elkabets M; Porgador A; Levin D; Azhari R; Swiatlo E; Ling E; Feldman G; Tal M; Dagan R; Mizrachi Nebenzahl Y Int J Mol Med; 2016 Apr; 37(4):1127-38. PubMed ID: 26935978 [TBL] [Abstract][Full Text] [Related]
6. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes. Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746 [TBL] [Abstract][Full Text] [Related]
7. Modular virus-like particles for sublingual vaccination against group A streptococcus. Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769 [TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757 [TBL] [Abstract][Full Text] [Related]
9. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant. Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812 [TBL] [Abstract][Full Text] [Related]
10. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510 [TBL] [Abstract][Full Text] [Related]
11. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF mBio; 2021 Feb; 12(1):. PubMed ID: 33622722 [TBL] [Abstract][Full Text] [Related]
12. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500 [TBL] [Abstract][Full Text] [Related]
13. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes. Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B mBio; 2019 Nov; 10(6):. PubMed ID: 31772056 [TBL] [Abstract][Full Text] [Related]
14. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Linghua Z; Xingshan T; Fengzhen Z Int Immunopharmacol; 2006 Aug; 6(8):1267-76. PubMed ID: 16782539 [TBL] [Abstract][Full Text] [Related]
16. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002 [TBL] [Abstract][Full Text] [Related]
17. Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion. Song T; Cao F; Huang X; Wu S; Zhou Y; Ngai T; Xia Y; Ma G Vaccine; 2024 Sep; 42(22):126022. PubMed ID: 38876839 [TBL] [Abstract][Full Text] [Related]
18. Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection. Azizi H; Mirzaeei H; Nasiri AA; Bazi A; Mirzapour A; Khatami M; Nahavandi KH; Azimi A; Yaghoobi H Exp Parasitol; 2018 Jun; 189():66-71. PubMed ID: 29729492 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus. Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096 [TBL] [Abstract][Full Text] [Related]
20. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model. Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]